Polaryx Therapeutics, Inc.
PLYX CIK: 0002075320
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
State of Incorporation WY
Business Address 140 EAST RIDGEWOOD AVENUE, PARAMUS, NJ, 07652
Mailing Address SOUTH TOWER, 140 E RIDGEWOOD AVENUE, PARAMUS, NJ, 07652
Phone 201-940-7236
Fiscal Year End 1231
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13D Beneficial ownership report (>5%) | February 5, 2026 | View on SEC |
| 424B4 Prospectus for IPO or offering | February 2, 2026 | View on SEC |
| 3 Initial insider ownership report | January 29, 2026 | View on SEC |
| 3 Initial insider ownership report | January 29, 2026 | View on SEC |
| 3 Initial insider ownership report | January 29, 2026 | View on SEC |
| 3 Initial insider ownership report | January 29, 2026 | View on SEC |
| 3 Initial insider ownership report | January 29, 2026 | View on SEC |
| 3 Initial insider ownership report | January 29, 2026 | View on SEC |
| 3 Initial insider ownership report | January 29, 2026 | View on SEC |
| S-1/A IPO registration amendment | January 27, 2026 | View on SEC |
IPO Filings
S-1 November 21, 2025
- Developing drugs for ultra-rare pediatric genetic brain diseases with no approved treatments (e.g., CLN2, CLN3, Krabbe, Sandhoff).
- Lead drug PLX-200 in late-stage trials (SOTERIA) with Orphan Drug status and Fast Track designation for CLN3 Batten disease.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.